| Literature DB >> 34629712 |
Barbara Manchec1,2, Nima Kokabi3, Govindarajan Narayanan1,2, Andrew Niekamp1,2, Constantino Peña1,2, Alex Powell1,2, Brian Schiro1,2, Ripal Gandhi1,2.
Abstract
Cancer has become the leading cause of mortality in America, and the majority of patients eventually develop hepatic metastasis. As liver metastases are frequently unresectable, the value of liver-directed therapies, such as transarterial radioembolization (TARE), has become increasingly recognized as an integral component of patient management. Outcomes after radioembolization of hepatic malignancies vary not only by location of primary malignancy but also by tumor histopathology. This article reviews the outcomes of TARE for the treatment of metastatic colorectal cancer, metastatic breast cancer, and metastatic neuroendocrine tumors, as well as special considerations when treating metastatic disease with TARE. Thieme. All rights reserved.Entities:
Keywords: hepatic metastasis; liver-directed therapies; radioembolization
Year: 2021 PMID: 34629712 PMCID: PMC8497082 DOI: 10.1055/s-0041-1732318
Source DB: PubMed Journal: Semin Intervent Radiol ISSN: 0739-9529 Impact factor: 1.780